Rowena Burns

Chair of Health Innovation Manchester

Rowena is the chair for Health Innovation Manchester with an approach to drive growth, which involves extensive joint working with the City’s universities, major hospitals, and industry partners.  Rowena is also chief executive of Manchester Science Partnerships (MSP), the UK’s largest science and technology park operator.

Rowena has an impressive track record in senior leadership, including previous roles as group director of the Manchester Airports Group and chief operating officer of Bruntwood, MSP’s majority shareholder.

Ben Bridgewater

Chief Executive, Health Innovation Manchester

Ben Bridgewater is Chief Executive of Health Innovation Manchester, an academic health science system that brings together health, academia and industry. The mission is to accelerate innovation into practice at pace and scale, so to transform the lives of Greater Manchester’s 2.8 million citizens.

He is a leading expert on health informatics, national clinical audit, clinical governance, healthcare transparency, patient experience measurement and digital transformation in healthcare, publishing numerous high profile academic outputs and delivering innovative IT tools for disseminating clinical outcomes to professionals and the public.

Prior to joining Health Innovation Manchester, Ben worked for global technology company DXC Technology as the Director of the Healthcare and Lifesciences Global Build Advisory Team. Until January 2016, he was a cardiac surgeon at the University Hospital of South Manchester for nearly 18 years.

Ben also provided clinical leadership for the UK national cardiac audit programme, as well as leading analyses that provides UK hospital and cardiac surgery mortality rates to the public. The programme is world-leading and associated with a 50% reduction in risk-adjusted mortality over 10 years.

Amanda Risino

Managing Director and Deputy CEO of Health Innovation Manchester

As an Executive member of the Health Innovation Manchester Board and deputy Chief Executive Officer, Amanda’s role is to build a culture of partnerships and collaboration to create a seamless pathway from discovery, science and industry engagement through to adoption and diffusion at pace and scale.

Amanda is passionate about transforming Health and Social Care by ensuring that strong relationships are built between clinicians, industry and academic partners to introduce cutting edge innovations, which will overall improve the Greater Manchester population’s health and wellbeing. She is proud of the contribution we make in HInM to improving the lives of patients and public. Amanda is a strong advocate of patient and public involvement in the co-design of health and social care. She strives for continuous improvement and is keen to deliver the best possible results for all concerned, to ensure that Manchester becomes a great place to live, work and grow old in.

Sir Howard Bernstein

Non Executive Director

Sir Howard Bernstein is the former Chief Executive of Manchester City Council (1998 – 2017) and former Head of Paid Service for the Greater Manchester Combined Authority (2011-2017).

He has driven Manchester’s regeneration, through strong public/private sector partnerships.

Key achievements include a leading role in: renewal of the centre following the 1996 terrorist bombing; securing Manchester as Host City for the highly successful 2002 Commonwealth Games; introduction of Metrolink and its on-going expansion across the connurbation; establishment of Manchester Airport plc in the mid-1980’s and its recent expansion; public sector reform, including the establishment of GM Combined Authority.

In 2014 he led negotiations with Government to secure a historic and groundbreaking Devolution Agreement for Greater Manchester. He also led the development of a Memorandum of Understanding between GM local authorities, NHS England and the GM CCGs to secure the devolution of health and social care funding in Greater Manchester.

External appointments include Deputy Chair of the HS2 Growth Task Force; Non-Executive Chair of Manchester Academic Health Science Centre.

Since retirement from Manchester City Council Sir Howard has taken up several strategic consultancy roles, including one with the University of Manchester and another with Deloitte LLP

Sir Howard Bernstein was knighted for his services in 2003.

Richard Topliss

Non Executive Director

Chair, Manchester Growth Company

RBS regional managing director Richard Topliss is the chair of The Growth Company. Richard has been based in the North West since 2000, originally running the corporate and commercial banking division of RBS in North Lancashire and Cumbria. He has more than three decades worth of experience in corporate banking and is responsible for a team of 328 staff, looking after businesses with turnover in excess of £2m across the North of England and North Wales.

In his role at RBS, Richard is a member of the National Leadership team and chair of the Regional Management team for the North, working closely with the North West’s Local Enterprise Partnerships. He has experience working directly with the public sector and local authorities such as Manchester City Council, with whom he has helped to establish a funding hub for social inclusion. In addition to his local authority experience, Richard is also directly engaged with the local business community as an active member of the CBI council in the North West and the North West Business Leadership Team.

Professor Peter Clayton

Interim Vice President, The University of Manchester and Dean of Faculty of Biology, Medicine and Health

Professor Clayton graduated from Manchester University Medical School in 1984 (Distinction in Paediatrics), having obtained a first class degree in Physiology & Pharmacology in 1981. He completed his early paediatric training around Manchester before embarking on an academic career in Paediatric Endocrinology. His MD thesis was on “Growth Patterns after Neuroaxis Irradiation in Childhood”. He spent time at the University of Virginia, USA as a MRC Travelling Fellow in 1990/1 with his work there primarily directed at molecular endocrinology in the laboratory.

He returned to Manchester to establish a research group of both clinicians and scientists, working under the broad remit of investigating normal and abnormal growth from clinical, biochemical and molecular perspectives. He took up a Senior Lectureship in Child Health in 1994, and was promoted to Professor of Child Health and Paediatric Endocrinology in 2001. He was lead for the Division of Human Development in the Manchester Medical School from 2001-2007. He was Director of the Institute of Human Development in the Faculty of Medical & Human Sciences 2014-2016.

Peter was appointed Head of the School of Medical Sciences and a member of the University’s Faculty of Biology, Medicine and Health (FBMH) in May 2016.

He has >200 publications on clinical and basic science aspects of paediatric endocrinology. He has served on the editorial boards of a number of endocrine journals (Hormone Research in Paediatrics, European Journal of Endocrinology and Clinical Endocrinology). He has been on the Councils of the Growth Hormone Research Society, the Society for Endocrinology UK, and the European Society of Paediatric Endocrinology, being Chair of the ESPE Corporate Liaison Board. He is currently Secretary-General for ESPE. He is on the medical committee of the UK Pituitary Foundation.

Sir David Dalton

Chief Executive of the Northern Care Alliance NHS Group

Sir David has been an NHS Chief Executive for over 22 years, serving at Salford Royal since 2001.

In April 2016, Sir David was appointed Group Chief Executive of the Northern Care Alliance NHS Group, which brings together staff and services of Salford Royal NHS Foundation Trust and The Pennine Acute Hospitals NHS Trust. The Alliance provides the benefits of scale but delivers this locally through multiple sites. It serves a population of over 1 million people across local communities bringing together over 17,000 staff, managing over 2,000 hospital beds and an operating budget of £1.3 billion.

Sir David was knighted in the 2014 New Year’s Honours for his services to Healthcare. During 2013 he was a member of the ‘Berwick Review Group’, which advised on patient safety improvements for England. He co-chaired a review of the ‘duty of candour’ in 2014 to support openness in reporting harmful events. In 2014 he advised the Secretary of State on the opportunities for providers of NHS care, including the publication of the ‘Dalton Review’ which recommended actions to assure the delivery of high quality healthcare through sustainable organisations.

Sir David is currently developing a new integrated care service (hospital, community, primary and social care) for the city of Salford, with its triple aim of improved population health outcomes, better user experience and lower cost. Under David’s leadership, Salford Royal has adopted a disciplined approach of applied ‘improvement science’ coupled with deep staff involvement. He is now developing the concept of ‘standardisation of best practice’ by creating a digital enterprise and seeking to apply this at scale, across multiple organisations.

He was founder chair of AQuA, NHS Quest and most recently, Haelo: each of which support organisations in their improvement activities. He established NWeHealth and currently services on the national review group advising the Secretary of State on IT and digital developments. He is Vice Chair of the Greater Manchester Academic Health Science Network – with the twin purpose of improving population health and creating a new relationship with industry across Greater Manchester. He is a Governor of the Health Foundation.

Sir Mike Deegan

Chief Executive, Manchester University NHS Foundation Trust

Sir Mike Deegan holds a first degree in Law and a Masters degree in Industrial Relations from the University of Warwick. He was previously Chief Executive at Warrington Hospital and then North Cheshire Hospitals NHS Trust. Mike was involved in the preparation of the Government’s NHS Plan in 2000 and has held the post of Director of Human Resources for the NHS
He has worked widely across the public sector including roles in local government and education.

Manchester University NHS Foundation Trust is the host trust for: GM National Institute for Health Research (NIHR) components (Biomedical Research Unit (BRU), Clinical Research Network (CRN), Clinical Research Facility (CRF)

Anthony Hassall

Chief Accountable Officer, NHS Salford Clinical Commissioning Group

A resident of Salford for 17 years, Anthony joined the NHS in 1998 and has undertaken a number of senior roles within primary and community care, the Department of Health, Cheshire and Merseyside Strategic Health Authority and in large teaching hospitals in Greater Manchester and Merseyside before joining Salford CCG in August 2015. Anthony has a strong background in developing strong, successful, strategic partnerships with health and social care organisations and believes strongly in the power of strong engagement with our local communities to ensure we deliver high performing services.

Malcolm Press

Vice-Chancellor, Manchester Metropolitan University

Malcolm Press was appointed as Vice-Chancellor of Manchester Metropolitan University in 2015, having previously held positions at the Universities of Birmingham, Sheffield, Manchester and UCL.

Malcolm is an ecologist with over 200 publications covering the impacts of climate and environmental change, tropical rain forest ecology, and subsistence farming in sub-Saharan Africa. He has studied plants and environments in a diverse range of ecosystems from the tropics to the high Arctic.

Malcolm is currently a trustee of the Royal Botanic Gardens Kew and WWF-UK. He is also a member of the Council of the All-Party Parliamentary University Group and HEFCE’s Strategic Advisory Committee on Leadership, Governance and Management. Previously, he has served as president of the British Ecological Society, a council member of the National Trust, a council member of the Society of Biology, and as a REF panel deputy chair.

Within Greater Manchester, Malcolm sits on the boards of Health Innovation Manchester, Corridor Manchester, and Manchester Science Partnerships.

Professor Dame Nancy Rothwell

President and Vice Chancellor of The University of Manchester

Professor Dame Nancy Rothwelljoined the Victoria University of Manchester in 1987, became Professor of Physiology in 1994 and held an MRC Research Chair from 1998 to 2010. Concurrent with her Faculty posts she has also held University roles as Vice-President for Research (2004–2007) and as Deputy President and Deputy Vice-Chancellor (2007–2010).

She was elected Fellow of the Royal Society in June 2004 and made Dame Commander of the Order of the British Empire in June 2005 in recognition of her services to science.

Professor Rothwell became President and Vice-Chancellor in July 2010 – the first woman to lead The University of Manchester or either of its two predecessor institutions. She was the founding President of the Royal Society of Biology and has also served as a non-executive director of AstraZeneca. She is currently Co-Chair of the Prime Minister’s Council for Science and Technology, a Deputy Lieutenant for Greater Manchester, Chair of Corridor Manchester Board, a member of the Greater Manchester Local Enterprise Partnership Board and a member of the Northern Powerhouse Partnership Board.

Professor Rothwell takes a strong and active interest in the public communication of science.

Jon Rouse CBE

Chief Officer, Greater Manchester Health and Social Care Partnership

Jon was appointed as Chief Officer for Greater Manchester Health and Social Care Partnership in July 2016 to coordinate the delivery of Greater Manchester’s strategy for the transformation of health and care services ‘Taking Charge Together’ as part of the wider devolution plans for public service reform.

Previously, Jon was Director General for Social Care, Local Government and Care Partnerships at the Department of Health. Other roles include Chief Executive, London Borough of Croydon; Chief Executive, Housing Corporation; Chief Executive, Commission for Architecture and the Built Environment.

Jon is a passionate advocate for life sciences and feels strongly that the research and evidence of the determinants of health are used to inform policy and change.

Lord Peter Smith

Greater Manchester Combined Authority Leader with responsibility for Healthy Lives & Quality Care

Peter Smith was born in Leigh in 1945. After the London School of Economics, Peter was a lecturer at Walbrook College, London, and Manchester College of Art and Technology in Manchester. In 1982 he obtained an MSc in Urban Studies at Salford University and was appointed an Honorary Doctor of Laws at Manchester Metropolitan University in 2012. He is married to Joy and has one daughter, Anna.

Peter Smith was elected to Wigan Council in 1978 and was Chairman of Finance from 1983 to 1991 when he became Leader of the Council. In 2011 he was made a Freeman of the Borough to mark his 20 years as Leader. In June 2000 he was elected Chairman of the Association of Greater Manchester Authorities and in 2011 Chair of the Greater Manchester Combined Authority. He is currently leading on Health Devolution.

Peter was a director Manchester Airport from 1986 to 2010 and is a past chairman.

Peter is active at the national, regional and sub-regional levels of local government. He was appointed as trustee of Leadership Centre for Local Government and has been appointed Chair from March 2010. He is also the vice-chairman of the Special Interest Group for Municipal Authorities (SIGOMA). At the regional level Peter has been Chairman of the North West Regional Assembly and chair of the Executive Board of the NWRA until he was appointed to the Board of the NWDA in November 2008.

In his free time, Peter enjoys gardening, reading (particularly political biographies) and relaxing with friends. He is a keen jazz fan and enjoys most sport but especially Rugby League. In June 1999 he was created a Life Peer with the title Lord Smith of Leigh. In Parliament he takes particular interest in local government, health and transport matters.

Roger Spencer

Chief Executive, The Christie NHS Foundation Trust

Roger was appointed Chief Executive at The Christie in March 2015, having previously worked as Interim Chief Executive and Chief Operating Officer.

Roger has managed significant service developments including satellite radiotherapy & chemotherapy centres across Greater Manchester, transforming delivery of Christie services to an outpatient model. He directed the establishment of Christie partnerships for pharmacy, pathology, specialist diagnostic services and private patients & our academic investment plan. Roger leads for Greater Manchester in the National Cancer Vanguard developing & testing new models of care. In 2016 Roger led the Trust to a CQC Outstanding rating and is in the top 15 chief executives ranked by the HSJ in 2017. Roger leads the Christie in delivering the first national Proton Therapy service in the UK, operational in 2018.

Roger holds an MBA, an honours degree in Nursing Studies, is a Registered Nurse and is an independent director of Southway Housing Trust.

Roger previously worked at Salford Royal, East Lancashire Hospitals & Greater Manchester SHA

John Stageman OBE

Chairman, Bionow

John  is  Chairman of Bionow Ltd, a member of the Biotechnology and Biological Sciences Research Council, a Board member of NWDA, Chairman of the HealthTech and Medicines Knowledge Transfer Network for the Technology Strategy Board (TSB) and an Honorary Professor in Life Sciences at the University of Manchester.

Dr Stageman started his career in ICI at Billingham working on large scale industrial biotechnology projects including Single Cell Protein and Biodegradable polymers from bacterial fermentation. He led the team that scaled up to the first large scale manufacturing process for Quorn. Moving into the Pharmaceutical business that became AstraZeneca, John was a constant champion of biotechnology and genomics leading new investments pharmacogenetics and recombinant protein development and pilot production. He was responsible for developing AstraZeneca’s competitive biopharmaceutical strategy, leading to the acquisition of Cambridge Antibody Technology and of MedImmune. After a period in a transitional role as General Manager of MedImmune Cambridge, John returned to the North West as Vice President of UK Science Affairs, retiring from Astra Zeneca in 2011.